Media

Thetford Mines, Quebec – March 21, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce an update in the development and use of its Adherize+ platform. With the aim of assisting and improving the follow-up of hormone-dependent breast cancer patients taking oral CDK 4/6 inhibitor therapy, the Corporation, through its Adherize+ platform, will develop the monitoring and follow-up algorithm for these patients in collaboration with oncology physicians and pharmacists

Thetford Mines, Quebec – February 29, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce that the debt settlement previously announced in its press release dated February 22, 2024 has been completed and the Corporation settled indebtedness to a creditor totalling $1,236,398 in exchange for the issuance of 4,000,000 Class A Shares of KDA (“Common shares”) at a price of $0.309 per Common share (the “Debt Settlement”).

Thetford Mines, Quebec – February 22, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce the appointments of Mr. Yves Marmet as General Manager and Chief Technology Officer and Ms. Marie-Hélène as Chief Operating Officer of its subsidiary Groupe Technologique KDA Inc. effective immediately.

Thetford Mines, Quebec – December 20, 2023 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce that it is working with several Quebec and Canadian pharmacy banners to ensure the performance of its pharmacological adherence software, Adherize+.

Thetford Mines, Quebec – December 8, 2023 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce the closing of a private placement with accredited investors totaling 11,250,000 units (the “Units”) at a price of $0.10 per Unit for total gross proceeds of $1,125,000 (the “Private Placement”).